Adial Pharmaceuticals, Inc. Royalty Expense
Adial Pharmaceuticals, Inc. (ADIL) reported Royalty Expense of $10.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RoyaltyExpense · last filed 2026-08-14
- Adial Pharmaceuticals, Inc. royalty expense for the quarter ending 2026-06-30 was $10.00K, a 0.00% change year-over-year.
- Adial Pharmaceuticals, Inc. royalty expense for the quarter ending 2026-03-31 was $10.00K, a 0.00% change year-over-year.
- Adial Pharmaceuticals, Inc. royalty expense for the quarter ending 2025-12-31 was $10.00K.
- Adial Pharmaceuticals, Inc. royalty expense for the quarter ending 2025-09-30 was $10.00K, a 0.00% change year-over-year.
- Adial Pharmaceuticals, Inc. royalty expense for fiscal 2025 was $40.00K.
- Adial Pharmaceuticals, Inc. royalty expense for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Adial Pharmaceuticals, Inc. royalty expense for fiscal 2023 was $40.00K, a 0.00% change from fiscal 2022.
- Adial Pharmaceuticals, Inc. royalty expense for fiscal 2022 was $40.00K, a 0.00% change from fiscal 2021.
| Period end | Royalty Expense 3 month | Royalty Expense 6 month | Royalty Expense 9 month | Royalty Expense 12 month | Royalty Expense 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $10.00K 10-Q · filed 2026-08-14 | $20.00K 10-Q · filed 2026-08-14 | $30.00K derived: sum of 3 quarters · filed 2026-08-14 | $40.00K derived: sum of 4 quarters · filed 2026-08-14 | |
| 2026-03-31 | $10.00K 10-Q · filed 2026-05-08 | $20.00K derived: sum of 2 quarters · filed 2026-05-08 | $30.00K derived: sum of 3 quarters · filed 2026-05-08 | $40.00K derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-12-31 | $10.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $20.00K derived: sum of 2 quarters · filed 2026-03-05 | $30.00K derived: sum of 3 quarters · filed 2026-08-14 | $40.00K 10-K · filed 2026-03-05 | |
| 2025-09-30 | $10.00K 10-Q · filed 2025-11-13 | $20.00K derived: sum of 2 quarters · filed 2026-08-14 | $30.00K 10-Q · filed 2025-11-13 | ||
| 2025-07-01 | $10.00K 10-Q · filed 2026-08-14 | ||||
| 2025-06-30 | $10.00K 10-Q · filed 2025-08-13 | $20.00K 10-Q · filed 2026-08-14 | -$10.00K derived: sum of 3 quarters · filed 2026-05-08 | $0.00 derived: sum of 4 quarters · filed 2026-05-08 | |
| 2025-03-31 | $10.00K 10-Q · filed 2026-05-08 | -$20.00K derived: sum of 2 quarters · filed 2026-05-08 | -$10.00K derived: sum of 3 quarters · filed 2026-05-08 | $0.00 derived: sum of 4 quarters · filed 2026-05-08 | |
| 2024-12-31 | -$30.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$20.00K derived: sum of 2 quarters · filed 2026-03-05 | -$10.00K derived: sum of 3 quarters · filed 2026-03-05 | $0.00 10-K · filed 2026-03-05 | $40.00K 10-K · filed 2025-03-04 |
| 2024-09-30 | $10.00K 10-Q · filed 2025-11-13 | $20.00K derived: sum of 2 quarters · filed 2025-11-13 | $30.00K 10-Q · filed 2025-11-13 | $40.00K derived: sum of 4 quarters · filed 2025-11-13 | |
| 2024-06-30 | $10.00K 10-Q · filed 2025-08-13 | $20.00K 10-Q · filed 2025-08-13 | $30.00K derived: sum of 3 quarters · filed 2025-08-13 | $40.00K derived: sum of 4 quarters · filed 2025-08-13 | |
| 2024-03-31 | $10.00K 10-Q · filed 2025-05-14 | $20.00K derived: sum of 2 quarters · filed 2025-05-14 | $30.00K derived: sum of 3 quarters · filed 2025-05-14 | $40.00K derived: sum of 4 quarters · filed 2025-05-14 | |
| 2023-12-31 | $10.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $20.00K derived: sum of 2 quarters · filed 2025-03-04 | $30.00K derived: sum of 3 quarters · filed 2025-03-04 | $40.00K 10-K · filed 2025-03-04 | |
| 2023-09-30 | $10.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $20.00K derived: sum of 2 quarters · filed 2024-11-13 | $30.00K 10-Q · filed 2024-11-13 | $40.00K derived: sum of 4 quarters · filed 2024-11-13 | |
| 2023-06-30 | $10.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $20.00K 10-Q · filed 2024-08-13 | $30.00K derived: sum of 3 quarters · filed 2024-08-13 | $40.00K derived: sum of 4 quarters · filed 2024-08-13 | |
| 2023-03-31 | $10.00K 10-Q · filed 2023-05-12 | $20.00K derived: sum of 2 quarters · filed 2024-04-01 | $30.00K derived: sum of 3 quarters · filed 2024-04-01 | $40.00K derived: sum of 4 quarters · filed 2024-04-01 | |
| 2022-12-31 | $10.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $20.00K derived: sum of 2 quarters · filed 2024-04-01 | $30.00K derived: sum of 3 quarters · filed 2024-04-01 | $40.00K 10-K · filed 2024-04-01 | |
| 2022-09-30 | $10.00K 10-Q · filed 2022-11-14 | $20.00K derived: sum of 2 quarters · filed 2022-11-14 | $30.00K 10-Q · filed 2023-11-14 | $40.00K derived: sum of 4 quarters · filed 2023-05-12 | |
| 2022-06-30 | $10.00K 10-Q · filed 2022-08-15 | $20.00K 10-Q/A · filed 2023-10-30 | $30.00K derived: sum of 3 quarters · filed 2023-05-12 | $40.00K derived: sum of 4 quarters · filed 2023-05-12 | |
| 2022-03-31 | $10.00K 10-Q · filed 2023-05-12 | $20.00K derived: sum of 2 quarters · filed 2023-05-12 | $30.00K derived: sum of 3 quarters · filed 2023-05-12 | ||
| 2021-12-31 | $10.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $20.00K derived: sum of 2 quarters · filed 2023-03-30 | $40.00K 10-K · filed 2023-03-30 | ||
| 2021-09-30 | $10.00K 10-Q · filed 2022-11-14 | $30.00K 10-Q · filed 2022-11-14 | |||
| 2021-03-31 | $10.00K 10-Q · filed 2022-05-16 | ||||
| 2020-12-31 | $40.00K 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |